Synthetic Antibody Mimetics Targeting PSMA for Prostate Cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer therapies, particularly monoclonal antibodies, face limitations such as immunological side-reactions, lack of oral bioavailability, and high production costs, necessitating the development of alternative approaches that can effectively target and treat prostate cancer with fewer side effects.
Innovation Solution
Development of synthetic antibody mimetics, like SyAM-P, which are bifunctional/multifunctional compounds that selectively bind to prostate-specific membrane antigen (PSMA) and modulate FcγRI receptors, redirecting immune responses to cancer cells, thereby enhancing immune signaling and phagocytic responses against prostate cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If monoclonal antibodies are used to target cancer cells, then immune response is enhanced, but immunological side-reactions occur
Solution Approach 1:
The patent creates synthetic antibody mimetics (SyAMs) that copy the essential binding functions of monoclonal antibodies without using actual antibody structures. These small molecule mimetics replicate the target-specific binding capability while avoiding the immunogenicity issues inherent to protein-based antibodies, thus resolving the contradiction between effective cancer targeting and immunological side-reactions
Solution Approach 2:
The invention employs small molecule synthetic compounds instead of expensive, complex monoclonal antibodies. These small molecules are more stable, have better pharmacokinetic properties, and can be administered orally, providing a cost-effective and sustainable alternative that maintains therapeutic efficacy while reducing complications associated with protein-based biologics
2Reliability
If monoclonal antibodies are used for cancer therapy, then immune signaling is enhanced, but oral bioavailability is lost
Solution Approach 1:
The patent replaces the protein-based mechanical structure of monoclonal antibodies with small molecule chemical structures. This substitution enables the therapeutic agent to withstand gastrointestinal degradation and be absorbed through the oral route, while still maintaining the ability to bind targets and activate immune responses through the designed binding moieties
Solution Approach 2:
The invention fundamentally changes the physical-chemical parameters of the therapeutic agent by transitioning from large protein molecules to small synthetic molecules. This parameter change includes reduced molecular weight, increased chemical stability, and improved membrane permeability, all of which enable oral administration while preserving immune-modulating functionality
3Reliability
If monoclonal antibodies are produced and administered, then cancer targeting is achieved, but production cost increases
Solution Approach 1:
The patent employs small molecule synthetic compounds that can be produced through conventional chemical synthesis methods, avoiding the expensive and complex bioprocessing required for monoclonal antibody production. This approach dramatically reduces manufacturing costs while maintaining targeted cancer cell binding capability through the designed PSMA-binding moieties
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
SyAM-P compounds demonstrate synergistic anticancer activity by stimulating both innate and adaptive immune responses, leading to effective targeting and eradication of prostate cancer cells, including metastatic cells, with potential for reduced side effects and improved treatment outcomes.
Implementation Method 1
bifunctional/multifunctional compounds which contain at least one cancer cell binding moiety which selectively binds to prostate specific membrane antigen (PSMA)
Implementation Method 2
an Fc receptor binding moiety which modulates an Fc immune receptor, preferably a FcγRI receptor... which can modulate (preferably, upregulate) a humoral response
Implementation Method 3
stimulating immune effector cells, thus increasing immune signaling and phagocytic and/or cytotoxic responses acting in a synergistic manner to assist in eliminating cancer cells
Data Source
AI summary
The present invention relates to compounds which function as antibody mimetic compounds. These compounds are bifunctional/multifunctional compounds which contain at least one cancer cell binding moiety which selectively binds to prostate specific membrane antigen (PSMA) and a FC receptor binding moiety which modulates an FC immune receptor, preferably a FcγRI receptor. Compounds according to the present invention bind selectively to cancer cells which upregulate PSMA and through that interaction, place the Fc receptor binding moiety of the compound in proximity to a Fc receptor, preferably a FcγRI receptor, which can modulate (preferably, upregulate) a humoral response in a patient to cancer cells. Through this biological action of the compounds according to the present invention, cancer cells, including metastatic cancer cells, especially prostate cancer cells can be immune regulated, resulting in the favorable therapy of cancer in a patient. Methods of using these compounds to treat cancer and/or reduce the likelihood of metastatis of cancer are additional aspects of the present invention.